OMERS ADMINISTRATION Corp Takes Position in Protalix BioTherapeutics, Inc. $PLX

Key Points

• OMERS ADMINISTRATION Corp acquired a new stake in Protalix BioTherapeutics, purchasing 179,300 shares valued at approximately $459,000, representing about 0.23% of the company.
• Several institutional investors significantly increased their positions in Protalix BioTherapeutics, with Northern Trust Corp boosting its holdings by an impressive 1,299.4% in the 4th quarter.
• Protalix BioTherapeutics' stock rating was recently downgraded from "strong-buy" to "buy," despite having an average rating of "Buy" and a consensus price target of $15.00.

OMERS ADMINISTRATION Corp purchased a new position in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 179,300 shares of the company's stock, valued at approximately $459,000. OMERS ADMINISTRATION Corp owned approximately 0.23% of Protalix BioTherapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PLX. Marshall Wace LLP purchased a new stake in Protalix BioTherapeutics in the fourth quarter worth about $192,000. Northern Trust Corp grew its position in shares of Protalix BioTherapeutics by 1,299.4% during the fourth quarter. Northern Trust Corp now owns 731,742 shares of the company's stock worth $1,376,000 after purchasing an additional 679,451 shares in the last quarter. Jane Street Group LLC grew its position in shares of Protalix BioTherapeutics by 147.2% during the fourth quarter. Jane Street Group LLC now owns 113,616 shares of the company's stock worth $214,000 after purchasing an additional 67,664 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in shares of Protalix BioTherapeutics by 24.1% during the fourth quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company's stock worth $55,000 after purchasing an additional 5,686 shares in the last quarter. Finally, Millennium Management LLC grew its position in shares of Protalix BioTherapeutics by 3.8% during the fourth quarter. Millennium Management LLC now owns 387,921 shares of the company's stock worth $729,000 after purchasing an additional 14,164 shares in the last quarter. Hedge funds and other institutional investors own 16.53% of the company's stock.

Insider Buying and Selling

In other news, Director Aharon Schwartz purchased 129,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The stock was bought at an average cost of $1.60 per share, with a total value of $206,400.00. Following the completion of the purchase, the director owned 303,000 shares in the company, valued at approximately $484,800. This represents a 74.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 6.50% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen cut Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Protalix BioTherapeutics currently has a consensus rating of "Buy" and an average target price of $15.00.

Protalix BioTherapeutics Stock Down 3.1%

Protalix BioTherapeutics stock traded down $0.05 during midday trading on Friday, reaching $1.54. 1,198,958 shares of the stock traded hands, compared to its average volume of 826,638. The stock's fifty day moving average is $1.53 and its 200-day moving average is $1.93. Protalix BioTherapeutics, Inc. has a 12 month low of $0.98 and a 12 month high of $3.10. The stock has a market cap of $122.79 million, a P/E ratio of -11.85 and a beta of -0.23.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.